SCREEN TEST COVID-19/INFLUENZA A+B/RSV

Screen Test Influenza A/B is a rapid qualitative test for self-diagnostic use that can detect influenza type A (including H1N1) and type B nucleoprotein antigen by extraction of a nasal swab or pharyngeal swab. The product serves as an aid in determining infection to influenza type A and B viruses. Screen Check Test Influenza A/B is an in vitro diagnostic Medical Device CE 0123. Read the warnings and operating instructions carefully. Authorization of 7/04/2021.

The rapid test for self-diagnostic use for SARS-CoV-2 antigen is a single-use in vitro immunochromatographic test designed for rapid qualitative detection of SARS-CoV-2 virus antigens. Screen Test Covid-19 Antigen is an in vitro diagnostic medical device CE 1434. Read the warnings and operating instructions carefully.

Influenza A+B Rapid Test – Product code: SC-0623-20 Rapid test for the qualitative detection of the Influenza A and Influenza B virus on samples of nasal swab, throat swab or nasal aspirate. The Influenza A + B rapid test is a rapid immunochromatographic test for the qualitative identification of influenza A and B antigens on nasal, pharyngeal or nasal aspirate swab samples. It is intended to assist in the rapid differential diagnosis of viral infections of influenza A and B. Influenza is an acute, highly contagious viral infection of the respiratory tract. It is a highly transmissible contagious disease through coughing and sneezing from suspended droplets containing the live virus. The peak of the flu usually occurs during the winter and autumn months each year. Type A viruses are usually more prevalent than type B and associated with more serious influenza outbreaks, while type B infections are usually milder.

Sars-Cov-2 Antigen + Flu A/B Rapid Test – Codice Prodotto: SC-1262-20 The Covid-19 Antigen Rapid Swab and Influenza A + B (nasopharyngeal swab) is a rapid immunochromatographic test for the qualitative detection of the antigens of the Sars-CoV-2, Influenza A and Influenza B viruses present in the human nasopharynx. For professional in vitro diagnostic use only. The separate results indicate the detection of Sars-CoV-2 and Influenza A + B antigens. The antigen is generally detectable in upper respiratory tract samples during the acute phase of the infection. Positive results indicate the presence of viral antigens, but a clinical correlation with the patient’s medical history and other diagnostic information is required to determine the infectious state. The positive results do not exclude bacterial infection or co-infections with other viruses.